ERBB2 and breast carcinoma: As T-DXd transitions from the highly controlled clinical trial setting to the real world, and its use extends from HER2-positive to HER2-low and may be HER2-ultra low metastatic breast cancer patients (depending on the results of the DESTINY-Breast06 trial), physicians must remain vigilant in monitoring the associated adverse effects and managing them effectively to optimize treatment benefits.